{"id":"abt-888","safety":{"commonSideEffects":[{"rate":"30-40%","effect":"Nausea"},{"rate":"20-30%","effect":"Vomiting"},{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting PARP enzymes, ABT-888 prevents DNA repair in cancer cells, leading to cell death. This mechanism is particularly effective in cancers with homologous recombination repair deficiencies.","oneSentence":"ABT-888 is a PARP inhibitor that works by blocking the action of poly (ADP-ribose) polymerase (PARP) enzymes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:20:24.349Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer, triple-negative breast cancer, ovarian cancer"}]},"trialDetails":[{"nctId":"NCT01366144","phase":"PHASE1","title":"Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-06-20","conditions":"Breast Carcinoma, Carcinoma of Unknown Primary, Endometrial Carcinoma","enrollment":94},{"nctId":"NCT03289910","phase":"PHASE2","title":"Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-24","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Atypical Chronic Myeloid Leukemia","enrollment":25},{"nctId":"NCT02152982","phase":"PHASE2, PHASE3","title":"Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-15","conditions":"Glioblastoma, Gliosarcoma","enrollment":447},{"nctId":"NCT01386385","phase":"PHASE1, PHASE2","title":"Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-06-20","conditions":"Lung Adenocarcinoma, Lung Adenocarcinoma, Mixed Subtype, Lung Large Cell Carcinoma","enrollment":53},{"nctId":"NCT00740805","phase":"PHASE1","title":"Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-08-18","conditions":"Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Solid Neoplasm","enrollment":81},{"nctId":"NCT01351909","phase":"PHASE1","title":"Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-05-02","conditions":"Locally Advanced Unresectable Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma","enrollment":35},{"nctId":"NCT03581292","phase":"PHASE2","title":"Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-11-06","conditions":"Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma","enrollment":38},{"nctId":"NCT01434316","phase":"PHASE1","title":"Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-11-11","conditions":"Advanced Malignant Solid Neoplasm","enrollment":121},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT02890355","phase":"PHASE2","title":"FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-09-01","conditions":"Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7","enrollment":123},{"nctId":"NCT02158507","phase":"NA","title":"Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2014-09-04","conditions":"Metastatic Triple Negative Breast Cancer","enrollment":20},{"nctId":"NCT02921256","phase":"PHASE2","title":"Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-11","conditions":"Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v7, Stage III Rectal Cancer AJCC v7","enrollment":363},{"nctId":"NCT01251874","phase":"PHASE1","title":"Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-11-22","conditions":"Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7","enrollment":44},{"nctId":"NCT01139970","phase":"PHASE1","title":"Veliparib and Temozolomide in Treating Patients With Acute Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-06-04","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","enrollment":66},{"nctId":"NCT01489865","phase":"PHASE1, PHASE2","title":"ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2011-01-03","conditions":"Metastatic Pancreatic Cancer","enrollment":64},{"nctId":"NCT01638546","phase":"PHASE2","title":"Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-07-27","conditions":"Recurrent Lung Small Cell Carcinoma","enrollment":97},{"nctId":"NCT01012817","phase":"PHASE1, PHASE2","title":"Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-11-03","conditions":"Metastatic Malignant Solid Neoplasm, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma","enrollment":88},{"nctId":"NCT01149083","phase":"PHASE2","title":"Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-06-30","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma","enrollment":77},{"nctId":"NCT02595905","phase":"PHASE2","title":"Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2016-09-15","conditions":"Metastatic BRCA Hereditary Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain","enrollment":344},{"nctId":"NCT01818063","phase":"PHASE2","title":"Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2013-04-25","conditions":"Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer","enrollment":9},{"nctId":"NCT00576654","phase":"PHASE1","title":"Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-03-18","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma","enrollment":73},{"nctId":"NCT00588991","phase":"PHASE1","title":"Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-02-04","conditions":"Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia","enrollment":12},{"nctId":"NCT01009788","phase":"PHASE2","title":"ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer","status":"COMPLETED","sponsor":"Steven J Isakoff, MD, PhD","startDate":"2009-11","conditions":"Breast Cancer, Metastatic Breast Cancer, BRCA1 Gene Mutation","enrollment":63},{"nctId":"NCT01585805","phase":"PHASE2","title":"Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-05-15","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8","enrollment":88},{"nctId":"NCT02163694","phase":"PHASE3","title":"A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-04-08","conditions":"Metastatic Breast Cancer","enrollment":513},{"nctId":"NCT01205828","phase":"PHASE2","title":"ABT-888 and Temozolomide for Liver Cancer","status":"TERMINATED","sponsor":"Georgetown University","startDate":"2010-08","conditions":"Hepatocellular Carcinoma","enrollment":16},{"nctId":"NCT02631733","phase":"PHASE1","title":"Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-05-31","conditions":"Malignant Solid Neoplasm","enrollment":18},{"nctId":"NCT02470585","phase":"PHASE3","title":"Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"TERMINATED","sponsor":"AbbVie","startDate":"2015-07-14","conditions":"Ovarian Cancer, Ovarian Neoplasm","enrollment":1140},{"nctId":"NCT03061188","phase":"PHASE1","title":"Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2017-05-23","conditions":"Advanced Solid Neoplasm, Aggressive Non-Hodgkin Lymphoma, Recurrent Solid Neoplasm","enrollment":15},{"nctId":"NCT01618357","phase":"PHASE1","title":"Pre-Operative Radiation and Veliparib for Breast Cancer","status":"COMPLETED","sponsor":"Richard Zellars","startDate":"2013-07-22","conditions":"Breast Cancer","enrollment":19},{"nctId":"NCT03044795","phase":"PHASE2","title":"Response to PARP Inhibitor Predicted by the RAD51 Assay","status":"WITHDRAWN","sponsor":"University Medical Center Groningen","startDate":"2019-11","conditions":"Cancer","enrollment":""},{"nctId":"NCT01827384","phase":"PHASE2","title":"MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-01-07","conditions":"Advanced Malignant Solid Neoplasm","enrollment":208},{"nctId":"NCT01711541","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-10-22","conditions":"Head and Neck Squamous Cell Carcinoma, Stage IVA Oropharyngeal Carcinoma AJCC v7, Stage IVB Oropharyngeal Carcinoma AJCC v7","enrollment":24},{"nctId":"NCT04774406","phase":"","title":"Arterial Hypertension Related to PARP Inhibitors (ArteRIB)","status":"COMPLETED","sponsor":"University Hospital, Caen","startDate":"2021-02-24","conditions":"Cancer","enrollment":2336},{"nctId":"NCT01642251","phase":"PHASE1, PHASE2","title":"Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-09-28","conditions":"Extensive Stage Small Cell Lung Carcinoma, Large Cell Lung Carcinoma, Neuroendocrine Carcinoma","enrollment":156},{"nctId":"NCT03123211","phase":"","title":"Expanded Access to Veliparib","status":"NO_LONGER_AVAILABLE","sponsor":"AbbVie","startDate":"","conditions":"Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound, Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Cancer","enrollment":""},{"nctId":"NCT02723864","phase":"PHASE1","title":"Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-08-09","conditions":"Neoplasms","enrollment":53},{"nctId":"NCT03400306","phase":"PHASE1","title":"A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer","status":"WITHDRAWN","sponsor":"AbbVie","startDate":"2021-11-15","conditions":"Cancer - Ovarian","enrollment":""},{"nctId":"NCT01506609","phase":"PHASE2","title":"Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer","status":"COMPLETED","sponsor":"AbbVie","startDate":"2012-01-23","conditions":"Metastatic Breast Cancer","enrollment":294},{"nctId":"NCT00989651","phase":"PHASE1","title":"Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-10-28","conditions":"Fallopian Tube Carcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma","enrollment":431},{"nctId":"NCT04774627","phase":"","title":"Pancytopenia Related to PARP Inhibitors (PancytoRIB)","status":"COMPLETED","sponsor":"University Hospital, Caen","startDate":"2021-02-07","conditions":"Cancer","enrollment":200},{"nctId":"NCT01063816","phase":"PHASE1","title":"A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-01","conditions":"Advanced Solid Tumors","enrollment":79},{"nctId":"NCT01123876","phase":"PHASE1","title":"Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-03","conditions":"Gastric Cancer","enrollment":60},{"nctId":"NCT02985658","phase":"","title":"Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer","status":"NO_LONGER_AVAILABLE","sponsor":"University of Washington","startDate":"","conditions":"Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation, Triple-Negative Breast Cancer","enrollment":""},{"nctId":"NCT04326023","phase":"","title":"Myelodysplastic Syndrome and Acute Myeloid Leukemia Related to PARP Inhibitors (MyeloRIB)","status":"COMPLETED","sponsor":"University Hospital, Caen","startDate":"2020-02-09","conditions":"Cancer","enrollment":178},{"nctId":"NCT02860819","phase":"PHASE2","title":"Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer","status":"COMPLETED","sponsor":"National Cancer Institute, Slovakia","startDate":"2016-08-01","conditions":"Testicular Cancer","enrollment":15},{"nctId":"NCT02264990","phase":"PHASE3","title":"Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-09-30","conditions":"Non-squamous Non-small Cell Lung Cancer","enrollment":595},{"nctId":"NCT03227016","phase":"PHASE1","title":"Study in Patients With SCLC of Veliparib in Combination With Topotecan","status":"UNKNOWN","sponsor":"Central European Society for Anticancer Drug Research","startDate":"2016-10","conditions":"Small Cell Lung Cancer SCLC","enrollment":30},{"nctId":"NCT02032277","phase":"PHASE3","title":"A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-04-02","conditions":"Triple Negative Breast Cancer","enrollment":634},{"nctId":"NCT02106546","phase":"PHASE3","title":"Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-04-10","conditions":"Squamous Non-Small Cell Lung Cancer","enrollment":970},{"nctId":"NCT01576172","phase":"PHASE2","title":"Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-03-30","conditions":"Castration-Resistant Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7","enrollment":159},{"nctId":"NCT02412371","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"AbbVie","startDate":"2015-04-30","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":48},{"nctId":"NCT01908478","phase":"PHASE1","title":"Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2013-10-02","conditions":"Pancreatic Cancer","enrollment":34},{"nctId":"NCT01749397","phase":"PHASE1","title":"Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-12-07","conditions":"Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7","enrollment":29},{"nctId":"NCT02289690","phase":"PHASE1, PHASE2","title":"Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-10-13","conditions":"Small Cell Lung Cancer","enrollment":221},{"nctId":"NCT01445522","phase":"PHASE1","title":"ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-12-03","conditions":"Neoplasms, Lymphoma","enrollment":35},{"nctId":"NCT01326702","phase":"PHASE1, PHASE2","title":"Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-07","conditions":"Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Adult Solid Neoplasm","enrollment":43},{"nctId":"NCT00994071","phase":"PHASE1","title":"A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-22","conditions":"Medulloblastoma, Pontine Glioma, Ependymoma","enrollment":9},{"nctId":"NCT02944396","phase":"PHASE1","title":"Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-12-23","conditions":"Non-Small Cell Lung Cancer","enrollment":25},{"nctId":"NCT01514201","phase":"PHASE1, PHASE2","title":"Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-02-01","conditions":"Anaplastic Astrocytoma, Brain Stem Glioma, Childhood Mixed Glioma","enrollment":66},{"nctId":"NCT01266447","phase":"PHASE2","title":"Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02","conditions":"Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma","enrollment":27},{"nctId":"NCT01540565","phase":"PHASE2","title":"Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-04-09","conditions":"BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ovarian Epithelial Tumor","enrollment":52},{"nctId":"NCT01459380","phase":"PHASE1","title":"Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-10-11","conditions":"Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma","enrollment":41},{"nctId":"NCT01281852","phase":"PHASE1","title":"Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-03-14","conditions":"Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified","enrollment":37},{"nctId":"NCT01051596","phase":"PHASE2","title":"A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2009-09","conditions":"Colorectal Cancer","enrollment":75},{"nctId":"NCT02305758","phase":"PHASE2","title":"Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-12-02","conditions":"Untreated Metastatic Colorectal Cancer","enrollment":130},{"nctId":"NCT00892736","phase":"PHASE1","title":"Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-04-20","conditions":"Basal-Like Breast Carcinoma, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier","enrollment":98},{"nctId":"NCT00770471","phase":"PHASE1","title":"ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2009-07-13","conditions":"Brain and Central Nervous System Tumors","enrollment":24},{"nctId":"NCT00804908","phase":"PHASE2","title":"A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-02","conditions":"Melanoma, Metastatic Melanoma, Skin Cancer","enrollment":346},{"nctId":"NCT01657799","phase":"PHASE2","title":"Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-10-19","conditions":"Brain Metastases From Non-small Cell Lung Cancer","enrollment":307},{"nctId":"NCT01113957","phase":"PHASE2","title":"A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-03","conditions":"Ovarian Cancer","enrollment":168},{"nctId":"NCT02210663","phase":"PHASE1","title":"A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-07","conditions":"Advanced Solid Tumors","enrollment":16},{"nctId":"NCT01145430","phase":"PHASE1","title":"Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-06-01","conditions":"Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma","enrollment":45},{"nctId":"NCT01477489","phase":"PHASE1","title":"Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2012-01","conditions":"Breast Cancer","enrollment":33},{"nctId":"NCT00526617","phase":"PHASE1","title":"A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients","status":"COMPLETED","sponsor":"AbbVie","startDate":"2007-08","conditions":"Non-hematologic Malignancies, Metastatic Melanoma, Breast Cancer","enrollment":41},{"nctId":"NCT01853306","phase":"PHASE1","title":"A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-03-18","conditions":"Oncology, BRCA Mutated, High Grade Serous Ovarian Cancer","enrollment":71},{"nctId":"NCT01199224","phase":"PHASE1","title":"To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid Tumors","status":"COMPLETED","sponsor":"AbbVie","startDate":"2010-06","conditions":"Solid Tumors","enrollment":27},{"nctId":"NCT00649207","phase":"PHASE1","title":"A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2008-03","conditions":"Brain Diseases, Brain Neoplasms, Central Nervous System Diseases","enrollment":80},{"nctId":"NCT01264432","phase":"PHASE1","title":"Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-01-01","conditions":"Adult Solid Neoplasm, Peritoneal Carcinomatosis, Recurrent Fallopian Tube Carcinoma","enrollment":34},{"nctId":"NCT01085422","phase":"PHASE1","title":"A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-04","conditions":"Prostate Cancer","enrollment":35},{"nctId":"NCT02009631","phase":"PHASE1","title":"A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-11","conditions":"Breast Cancer, Ovarian Cancer, Colon Cancer","enrollment":45},{"nctId":"NCT01617928","phase":"PHASE1","title":"A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-05","conditions":"Solid Tumors","enrollment":12},{"nctId":"NCT02483104","phase":"PHASE1","title":"Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-07","conditions":"Ovarian Cancer","enrollment":9},{"nctId":"NCT01589419","phase":"PHASE1","title":"A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-06","conditions":"Locally Advanced Rectal Cancer","enrollment":32},{"nctId":"NCT03032614","phase":"PHASE2","title":"Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients","status":"WITHDRAWN","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2017-09-30","conditions":"Breast Cancer Stage IV, Ovarian Cancer, BRCA1 Mutation","enrollment":""},{"nctId":"NCT02831179","phase":"PHASE1","title":"Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor","status":"WITHDRAWN","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2017-12","conditions":"Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma, Merkel Cell Carcinoma","enrollment":""},{"nctId":"NCT01495351","phase":"PHASE1","title":"Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma","status":"COMPLETED","sponsor":"AHS Cancer Control Alberta","startDate":"2011-10","conditions":"Multiple Myeloma","enrollment":19},{"nctId":"NCT01104259","phase":"PHASE1","title":"Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2010-07","conditions":"Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Hereditary Breast/Ovarian Cancer - BRCA1","enrollment":50},{"nctId":"NCT00553189","phase":"PHASE1","title":"Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-08-09","conditions":"Solid Tumors, Lymphomas","enrollment":31},{"nctId":"NCT01419548","phase":"PHASE1","title":"ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2011-07-29","conditions":"Neoplasms","enrollment":""},{"nctId":"NCT01026493","phase":"PHASE1, PHASE2","title":"Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2010-07","conditions":"Brain and Central Nervous System Tumors","enrollment":257},{"nctId":"NCT01306032","phase":"PHASE2","title":"Phase II ABT-888 With Cyclophosphamide","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-01-12","conditions":"Ovarian Cancer, Primary Peritoneal Cancer, Serous Carcinoma Cancer","enrollment":124},{"nctId":"NCT01472783","phase":"PHASE1, PHASE2","title":"Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation","status":"COMPLETED","sponsor":"Vejle Hospital","startDate":"2011-11","conditions":"Recurrent, Epithelial Ovarian Cancer","enrollment":49},{"nctId":"NCT02033551","phase":"PHASE1","title":"A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-12","conditions":"Breast Cancer, Ovarian Cancer, Colon Cancer","enrollment":47},{"nctId":"NCT01017640","phase":"PHASE1","title":"Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-10","conditions":"Solid Neoplasm","enrollment":20},{"nctId":"NCT01560104","phase":"PHASE2","title":"A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-02","conditions":"Non-Small -Cell Lung Cancer","enrollment":160},{"nctId":"NCT01154426","phase":"PHASE1","title":"ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-05","conditions":"Adult Solid Neoplasm, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier","enrollment":31},{"nctId":"NCT01690598","phase":"PHASE1, PHASE2","title":"Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status","status":"COMPLETED","sponsor":"Vejle Hospital","startDate":"2012-11","conditions":"Ovarian Cancer","enrollment":22},{"nctId":"NCT01281150","phase":"PHASE1","title":"Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-01","conditions":"Adult Solid Neoplasm, Estrogen Receptor Negative, Estrogen Receptor Positive","enrollment":22},{"nctId":"NCT00535119","phase":"PHASE1","title":"Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-09","conditions":"Adult Solid Neoplasm, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier","enrollment":107}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ABT-888, veliparib","veliparib","Veliparib"],"phase":"phase_2","status":"active","brandName":"ABT-888","genericName":"ABT-888","companyName":"AbbVie (prior sponsor, Abbott)","companyId":"abbvie-prior-sponsor-abbott","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABT-888 is a PARP inhibitor that works by blocking the action of poly (ADP-ribose) polymerase (PARP) enzymes. Used for Metastatic breast cancer, triple-negative breast cancer, ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":7,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}